Vogo .3MG Tab 15S

Tablet

Type 2 diabetes mellitus (post‑prandial/high after-meal blood sugar control) as an add-on to diet and exercise, alone or with other antidiabetic medicines.

Voglibose is an alpha‑glucosidase inhibitor that slows carbohydrate digestion in the intestine by inhibiting enzymes that break down complex sugars. This reduces absorption of glucose after meals and helps control post‑meal blood sugar spikes.

Tablet for oral use. Usually taken just before meals (or with the first bite of food) as prescribed by the doctor. Follow diet/exercise plan; if you skip a meal, skip the dose for that meal. Do not crush unless advised.

Flatulence, abdominal pain, diarrhoea, bloating, nausea

May cause gastrointestinal side effects; start and titrate as advised. Risk of hypoglycaemia increases when used with insulin or sulfonylureas—carry glucose and treat low sugar with glucose/dextrose (not table sugar) when on alpha‑glucosidase inhibitors. Use with caution in liver disease; monitor liver enzymes if advised. Avoid/consult doctor in inflammatory bowel disease, intestinal obstruction, colonic ulceration, or conditions worsened by increased gas. Not indicated for type 1 diabetes or diabetic ketoacidosis.

Insulin, sulfonylureas (e.g., glimepiride, gliclazide) may increase hypoglycaemia risk; intestinal adsorbents and digestive enzyme preparations may reduce effect; corticosteroids, thiazide diuretics, thyroid hormones and sympathomimetics may worsen glycaemic control; other antidiabetics (metformin, pioglitazone, DPP-4 inhibitors) may have additive glucose-lowering effect.

Store below 25°C in a dry place, protected from light and moisture. Keep in original blister pack and out of reach of children.

Voglibose 0.3 mg tablets (generic), Vogli 0.3 Tablet, Vobose 0.3 Tablet, Voglib 0.3 Tablet, Voglitor 0.3 Tablet